Synageva BioPharma Corp
MAC Clause: How the Circumstances Impact Pall
A fire at one of Pall’s factories would be a MAC. If a major Pall customer left because they didn’t want to work with Danaher, it isn’t a MAC.
MAC Clause: How Can Danaher Walk Away?
The MAC clause has been paraphrased to limit the legalese. This part lays out the circumstances under which Danaher (DHR) can walk away from its deal with Pall (PLL).
Pall-Danaher Transaction: What You Should Know about Danaher
Danaher (DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services.
Pall-Danaher Transaction: An Overview of Pall
Pall (PLL) is a supplier of filtration, separation, and purification technologies. Pall divides its business segments into Life Sciences and Industrial.
Backing Out of the Synageva BioPharma Deal, Part 3
Things like acts of war and natural disasters aren’t MACS unless they disproportionately affect Synageva relative to other early-clinical-stage biopharmaceutical companies.
Backing Out of the Synageva BioPharma Deal, Part 1
In this case, the material adverse change clause lays out the circumstances under which Alexion could back out of its deal with Synageva. This clause is one of the first things that arbitrageurs look at.
Synageva BioPharma: A Pipeline of Therapeutic Programs
Synageva has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.
Alexion Pharmaceuticals Would Benefit from Synageva Pipeline
This deal is about buying a pipeline and intellectual property. Synageva Biopharma’s drug Kanuma is used for the treatment of LAL D, a childhood disease.
The Synageva–Alexion Merger: Stock and Cash Considerations
The Synageva–Alexion transaction is a merger involving cash and stock considerations. These deals have a longer time frame than cash-tender deals, which can close in as little as 45 days.
Alexion Pharmaceuticals Pays up to Get Synageva BioPharma
The transaction’s risk-to-reward ratio explains why the spread is wide. In fact, it looks like Synageva has some good protections in the material adverse effect clause.